
## **IS MISE CARA BRAIN DISEASE FOUNDATION** 

## **REGISTRATION NUMBER 1200525 ANNUAL REPORT 2024** 

Included  are  the  accounts  of  Is  Mise  Cara  Brain  Disease  Foundation (henceforth "Foundation") for the date ended March 31[st ] 2024, which are set out  on  pages  1  and  2  of  attached  Charity  Commission  form  CC16a. Accounts for Year 2 (2nd financial year) are hereby stipulated as between April 1st 2023 and March 31[st ] 2024. 

This  is  the  second  annual  report  of  the  Trustee  /  Directors  of  the Foundation. 

## **UK Charity Commission Registration:** 

The founders and supporters of the Foundation were able to achieve all the preparation and documentation required by the Commission and consequently registration was granted on 29th September 2022. 

## **Aim and Purposes:** 

The Foundation was set up to provide support and wellbeing for families and their carers who are undergoing brain disease treatment especially children.  This  will  also  include  providing  breaks  and  holidays.  The Foundation's purposes remain the same as per the Registration application. 



## **Objectives and Activities:** 

The Foundation's overall objectives remain the same. Consequently, the short-term tasks are: 

**Fund  Raising:** During  this  financial  year,  the  Management  Team  has approved and actioned fundraising through events, donations from book sales, additional sponsorship options, and general volunteer donations. We made plans to be able to have merchandise for sale to enhance income in the year 24/25. 

**Grants:** Considerations and discussions were had as to how the Foundation might offer patients and their families locally, to have holiday opportunities in the vicinity. Good feedback was received from the Leeds Hospital Paediatric Oncology and from the Penny Fields School. 

**Policies:** The following policy documents were put in place: 






Safeguarding Conflict of Interest Complaints Bullying and Harassment Grant Making 

Additional policies will be developed, including: 










Financial rules 

Social Media Privacy Health and wellbeing GDPR - Data Protection Health and Wellbeing Investment policy Money laundering Disaster management 

**Website:** The  Foundation  continued  to  improve  and  ensure  that  the website is fit for purpose. 



Relationship  building:  The  Foundation  continued  to  build  relationships with both the medical and educational professions to ensure the neediest will be able to benefit from the facilities we are hopeful of putting in place. 

In Year 3, we will attempt sales of merchandise to sell via the Foundation's eCommerce-based website. 

The Foundation will also seek sponsorship and donor funding and submit grant funding proposals. 

## **Achievement and Performances:** 

The  Foundation's  website  has  since  been  improved  in  the  light  of experience: www.carabraindiseasefoundation.com 

## Donations: 

Donations were received amounting to £4335 during the financial year to the  31.3.2024.  This  includes  donations  from  the  Foundations  follow-up events in Leeds. 

- The Foundation launch event in November 2023 which raised a total of £l800.00. 

- The follow-up event on St Patrick's Day (March 17[th,] 2024) raised a further £351.00. 

- Donations  received  from  Finncara  Consulting  Ltd.,  amounted  to £392.40. 

- A US sponsor donated £500. 

## **Grants Made:** 

Through our relationship with the Leeds Hospital Paediatric Oncology Unit and the Penny Fields School we were made aware of individual families in particular need over the Christmas period and the Foundation was able to make grants to these families though the organisations concerned. The grants totalled £750. 

## **Relationship Building** 



Contacts in Leeds have continued with the paediatric oncology professionals and special needs schools for discussions in anticipation of finding  appropriate  families  to  receive  short  breaks.  Likewise,  the Foundation has been in touch with the Great Ormond Street Hospital to ascertain their potential interest in the Foundation and their needs. 

Contacts were also made with a view to corporate sponsorship, including HSBC our bankers and a US corporation. 

Contacts have been made with local businesses with a view to engaging with them to secure support and potential sponsorship. 

The Vice Chancellor of Leeds University has been contacted and a meeting has been arranged in July 2024 with a view to a potential collaboration. 

Contact has been maintained with the Yorkshire Brain Disease Charity with a view to collaboration. 

Contacts have been made with property agents in York to ascertain the viability of property rental to support patients and families. Conversations are ongoing as we seek funding to enable us to provide long-term rental services to patients and families. 

## **Volunteers** 

Volunteer recruitment was undertaken, especially in the Leeds area and good contact here was again made with Leeds Teaching and Hospital Trust and Penny Fields, a local special needs school. We already have many volunteers who are based here in the UK and abroad. 

## **Financial Review:** 

Considering the Foundation has only been truly operational with a banking service for a period of just over 1.5 years this has been a positive start financially. 



The only costs so far have been bank charges and IT costs. The balance in the account as at 31[st  ] March 2024 was £5486, an increase of £3389 from £2097. 

## **Administrative Information** 

Foundation Trustee/Directors: 




- Charles Stevens 

- John Croke 

- Claudia Rusenescu 

## **Management Committee** 







- Chair and Trustee Director, Charles Stevens Trustee Director, John Croke Trustee Director, Claudia Rusenescu Chief Executive Officer, Dr Kieran Mervyn Chief Marketing Officer, Faye Mervyn Advisor and Volunteer, Khalid Mukhtar 

Email: ismisecara@gmail.com 

Approved by the Is Mise Cara Board on 13.5.2024 and signed on their behalf by Charles Stevens, Lead Trustee. Copy minutes attached. 



## **IS MISE CARA BRAIN DISEASE 1200525 FOUNDATION** 

## **Receipts and paymentsmentsentsntss accountsntss** 

**Receipts and CC16 paymentsmentsentsntss accountsntss a For the** 1.4.2023 31.3.202 **period To** 4 **from** 

**Section A Receipts and payments** 


|**payments**||||||
|---|---|---|---|---|---|
|**A1 Receipts**|**Unrest**<br>**ricted**<br>**funds**<br>**to the**<br>**nearest**<br>**£**<br>**4,335**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>4,335<br>**-**<br>**-**<br>**Nil**|**Restri**<br>**cted**<br>**funds**<br>**to the**<br>**nearest**<br>**£**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endo**<br>**wmen**<br>**t**<br>**funds**<br>**to the**<br>**neares**<br>**t £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Total**<br>**funds**<br>**to the**<br>**neares**<br>**t £**<br>4335<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**4,335**<br>**-**<br>**-**<br>**Nil**|**Last year**<br>**to the**<br>**nearest £**|
|Donations|**4,335**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
|**_Sub_**<br>**_total_**_(Gross_<br>_income for AR)_|||||**-**|
|||||||
|**A2 Asset and**<br>**investment**<br>**sales, (see**<br>**table).**||||||
||**-**|**-**|**-**|**-**||
||**-**|**-**|**-**|**-**|**-**|
|**_Sub total_**|**Nil**|**-**|**-**|**Nil**|**-**|





|**_Total receipts_**|4335||**-**||**-**||4335||**-**|
|---|---|---|---|---|---|---|---|---|---|
|**A3 Payments**||||||||||
|Bank Charges|67||**-**||**-**||**67**||**-**|
|IT Costs|129||**-**||**-**||**129**||**-**|
|Grants Made|750||**-**||**-**||**750**||**-**|
||**-**||**-**||**-**||**-**||**-**|
||**-**||**-**||**-**||**-**||**-**|
||**-**||**-**||**-**||**-**||**-**|
||**-**||**-**||**-**||**-**||**-**|
||**-**||**-**||**-**||**-**||**-**|
||**-**||**-**||**-**||**-**||**-**|
|**_Sub total_**||||||||||
||**946**||**-**||**-**||**946**||**-**|



|**A4 Asset and**|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**investment**|||||||||||||||||
|**purchases,**|||||||||||||||||
|**(see table)**|||||||||||||||||
||**-**||**-**||||**-**||||**-**||||||
||**-**||**-**||||**-**||||**-**||||||
|**_Sub total_**|||||||||||||||||
||**Nil**||**-**||||**-**||||**Nil**||**-**||||
||||||||||||||||||
|**_Total_**|||||||||||||||||
|**_payments_**|**946**|||**-**||||**-**|||**946**|||**-**|||
||||||||||||||||||
|**_Net of_**|||||||||||||||||
|**_receipts/(pay_**|||||||||||||||||
|**_ments)_**|**3,389**||||**-**||||**-**||**3,389**||||**-**||
|**A5 Transfers**|||||||||||||||||
|**between funds**|**-**||||**-**||**-**||||**-**||||**-**||
|**A6 Cash funds**|||||||||||||||||
|**last year end**|**-**||||**-**||**-**||||**-**||||**-**||
|**_Cash funds_**|||||||||||||||||
|**_this year end_**|**2,097**||||**-**||||**-**||**2,097**||||**-**||





|**Section B Statement of assets and**<br>**liabilities at the end of the period**|**Section B Statement of assets and**<br>**liabilities at the end of the period**|**Section B Statement of assets and**<br>**liabilities at the end of the period**|**Section B Statement of assets and**<br>**liabilities at the end of the period**||
|---|---|---|---|---|
|**Categories**<br>**B1 Cash**<br>**funds**<br>**B2 Other**<br>**monetary**<br>**assets**|**Details**<br>HSBC<br>**_Total cash_**<br>**_funds_**<br>(agree balances with<br>receipts and payments<br>account(s))<br>**Details**|**Unres**<br>**tricte**<br>**d**<br>**funds**<br>**to**<br>**neares**<br>**t £**<br>**5,486**<br>**-**<br>**-**<br>**5,486**<br>Agree<br>ment<br>Error<br>**Unres**<br>**tricte**<br>**d**<br>**funds**<br>**to**<br>**neares**<br>**t £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Restri**<br>**cted**<br>**funds**<br>**to**<br>**neares**<br>**t £**<br>**-**<br>**-**<br>**-**<br>**-**<br>OK<br>**Restri**<br>**cted**<br>**funds**<br>**to**<br>**neares**<br>**t £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowm**<br>**ent**<br>**funds**<br>**to nearest**<br>**£**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||**-**|
|||||OK|
|||||**Endowm**<br>**ent**<br>**funds**<br>**to nearest**<br>**£**|
|||**-**|**-**|**-**|
|||**-**|**-**|**-**|
|||**-**|**-**|**-**|
|||**-**|**-**|**-**|
|||**-**|**-**|**-**|
|||**-**|**-**|**-**|



|**B3**<br>**Investment**<br>**assets**|**Details**|**Fund**<br>**to**<br>**which**<br>**asset**<br>**belong**<br>**s**<br>**0**|**Cost**<br>**(option**<br>**al)**<br>**-**<br>**-**<br>**-**|**Current**<br>**value**<br>**(optional)**|
|---|---|---|---|---|
|||**0**|**-**|**-**|
||||**-**|**-**|
||||**-**|**-**|





**-** 

## **Details** 

## **B4 Assets retained for the charity’s own use** 

## **Details** 

**B5 Liabilities** Signed by one or two trustees on Signature behalf of all the trustees 


|**Fund**<br>**to**<br>**which**<br>**asset**<br>**belong**<br>**s**<br>**Cost**<br>**(option**<br>**al)**<br>0<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund**<br>**to**<br>**which**<br>**liabilit**<br>**y**<br>**relates**<br>**Amoun**<br>**t due**<br>**(option**<br>**al)**<br>0<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>CBSTEVENS<br>J CROKE|**Current**<br>**value**<br>**(optional)**|
|---|---|
||**-**|
||**-**|
||**-**|
||**-**|
||**-**|
||**-**|
||**-**|
||**-**|
||**-**|
||**When due**<br>**(optional)**|
|||
|||
|||
|||
|||
|||
||Date of<br>approval|
|CBSTEVENS|13/<br>05/2024<br>14/05/20|
|J CROKE||





||**IS MISE CARA BRAIN DISEASE FOUNDATION**<br>|**IS MISE CARA BRAIN DISEASE FOUNDATION**<br>|**IS MISE CARA BRAIN DISEASE FOUNDATION**<br>|**1200525**|**CC16a**|
|---|---|---|---|---|---|
||**For the period**<br>**from**|29.9.2022|**To**|31.3.2023||
|||||||
|**Section A Receipts and payments**||||||
|**A1 Receipts**<br>Donations<br>**4,335**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>4335<br>**-**<br>**-**<br>**_Sub total_ Nil**<br>**_Total receipts_**<br>4335<br>**A3 Payments**<br>Bank Charges<br>67<br>IT Costs<br>129<br>Grants Made<br>750<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**_Sub total_                          946**<br>**-**<br>**-**<br>**_Sub total_  Nil**<br>**_Total payments_                      946**<br>**_Net of receipts/(payments)_                   3,389**<br>**A5 Transfers between funds**<br>**-**<br>**A6 Cash funds last year end**<br>**-**<br>**_Cash funds this year end_                   2,097**<br>**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**_Sub total_**_(Gross income for AR)_<br>**A2 Asset and investment sales,**<br>**(see table).**<br>**A4 Asset and investment**<br>**purchases, (see table)**||**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Restricted**<br>**funds**|**to the nearest £**<br>**Endowment**<br>**funds**|**Total funds**<br>**to the nearest £**<br>4335<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**4,335**<br>**-**<br>**-**<br>**Nil**<br>4335<br>**67**<br>**129**<br>**750**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**946**<br>**-**<br>**-**<br>**Nil**<br>**946**<br>**3,389**<br>**-**<br>**-**<br>**2,097**|**Last year**<br>**to the nearest £**|
||||**-**||**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**4,335**|**-**|
|||||||
||||**-**|**-**||
||||**-**|**-**|**-**|
||||**-**|**Nil**|**-**|
|||||||
||||**-**||**-**|
|||||||
||||**-**|**67**|**-**|
||||**-**|**129**|**-**|
||||**-**|**750**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**946**|**-**|
|||||||
||||**-**|**-**||
||||**-**|**-**||
||||**-**|**Nil**|**-**|
|||||||
||||**-**|**946**|**-**|
|||||||
|||**-**|**-**|**3,389**|**-**|
|||**-**|**-**|**-**|**-**|
|||**-**|**-**|**-**|**-**|
|||**-**|**-**|**2,097**|**-**|





## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B3 Investment assets**<br>**B5 Liabilities**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>Signed by one or two trustees on<br>behalf of all the trustees|**Details**<br>HSBC<br>**Details**<br>**Details**<br>**Details**<br>**Details**<br>Signature<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))|**to nearest £**<br>**to nearest £**<br>**5,486**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**5,486**<br>**-**<br>Agreement Error<br>OK<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**0**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>0<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>0<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>CB STEVENS<br>J CROKE<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**|**Endowment funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due (optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of approval|
||||5/13/2024<br>5/14/2024|
|||||



